(Q33396136)

26 July 2017

title

Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma (English)

1 reference

metastatic renal cell carcinoma

26 July 2017

1 reference

1 reference

Marija Bojic

3

0 references

author name string

Wolfgang Lamm

1

1 reference

26 July 2017

Ursula Maria Vogl

2

1 reference

26 July 2017

Christoph Zielinski

4

1 reference

26 July 2017

Christoph Klingler

5

1 reference

26 July 2017

Gero Kramer

6

1 reference

26 July 2017

Manuela Schmidinger

7

1 reference

26 July 2017

publication date

8 July 2011

1 reference

26 July 2017

1 reference

26 July 2017

volume

51

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

101-106

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Sequential sorafenib and sunitinib for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2011.589404

10.3109/0284186X.2011.589404

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference